BTG1 inactivation and mutations promote lymphoma dissemination. (A) Flow cytometry quantification of TMD8 cells (GFP⁺, human CD19⁺) in the spleen (left) and liver (right) of recipient NSG mice 5 weeks after intrasplenic xenograft (TMD8-BTG1^WT, n = 17 BTG1^−/−, n = 20; BTG1^rescue, n = 9; Rescue L26P, n = 4, Rescue G66D, n = 5, Rescue I1115V, n = 5). (B) Macroscopic examination and (C) immunohistochemical human CD20 staining of the liver of TMD8-BTG1^WT and TMD8-BTG1^−/−recipients. (D) Quantification of tumoral extension by human CD20 immunohistochemical staining of NSG mice brains after stereotaxic injection of TMD8-BTG1^−/−, TMD8-BTG1^WT, or TMD8-BTG1^rescue cells in the right hemisphere (n = 5) and representative images of human CD20 staining. Values represent mean or mean ± SEM; ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001; using one-way ANOVA with Tukey multiple comparisons test in panel A or Mann-Whitney test in panel D. ANOVA, analysis of variance; ns, not significant; SEM, standard error of the mean.